Shareholder alert: the law offices of vincent wong launch investigation of sarepta therapeutics, inc. for possible breaches of fiduciary duty

New york--(business wire)--the law offices of vincent wong are investigating sarepta therapeutics, inc. (nasdaq:srpt) in relation to possible breaches of fiduciary duty by the board of directors. click here to learn about the investigation: http://docs.wongesq.com/srpt-info-request-form-1068. there is no cost or obligation to you. on january 15, 2016, the u.s. food and drug administration (the “fda”) released a statement by an agency advisory committee that cast significant doubt on the approval prospects of sarepta’s muscular dystrophy drug eteplirsen. the agency’s internal review of eteplirsen stated, in part, that “[a]lthough fda is prepared to be flexible with respect to a devastating illness with no treatment options, we cannot approve drugs for which substantial evidence of effectiveness has not been established.” following this news, sarepta stock has fallen as much as $18.25 per share, or nearly 58 percent on january 15, 2016 during intraday trading. to obtain additional information, contact vincent wong, esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/srpt-info-request-form-1068. vincent wong, esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. attorney advertising. prior results do not guarantee similar outcomes.
SRPT Ratings Summary
SRPT Quant Ranking